Pharmaceuticals, Biotechnology and Life Sciences
Joe Wiley, CEO of Amryt, said Amryt has an ambitious plans for the remainder of 2018 as it looks forward to…
Amryt has begun with “EASE”, the Phase 3 clinical trial of AP101, its lead drug candidate, which offers a potential treatment for a rare genetic skin disorder that causes fragile skin.
Amryt is on track to begin the phase 3 trial at the end of March for its new skin healing treatment in an orphan disease, with regulatory authority discussions now completed with Food and Drug Administration (FDA) and European Medicines Agency (EMA) and the design of the clinical trial established.
Amryt has secured a patent in Japan for its skin disorder drug candidate Episalvan, and it is waiting to kick off the third phase clinical trial by the end of March 2017.